REATA PHARMACEUTICALS INC-A (RETA) Stock Price, Forecast & Analysis
NASDAQ:RETA • US75615P1030
RETA Key Statistics, Chart & Performance
The current stock price of RETA is 172.36 USD. In the past month the price increased by 1.99%. In the past year, price increased by 585.87%.
RETA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RETA. When comparing the yearly performance of all stocks, RETA is one of the better performing stocks in the market, outperforming 99.84% of all stocks.
RETA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RETA. While RETA seems to be doing ok healthwise, there are quite some concerns on its profitability.
RETA Financial Highlights
Over the last trailing twelve months RETA reported a non-GAAP Earnings per Share(EPS) of -2.98. The EPS increased by 64.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.43% | ||
| ROE | -100.38% | ||
| Debt/Equity | 0.84 |
RETA Forecast & Estimates
15 analysts have analysed RETA and the average price target is 175.9 USD. This implies a price increase of 2.05% is expected in the next year compared to the current price of 172.36.
For the next year, analysts expect an EPS growth of 20.24% and a revenue growth 3350.89% for RETA
RETA Ownership
RETA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.08 | 967.332B | ||
| JNJ | JOHNSON & JOHNSON | 20.81 | 594.88B | ||
| MRK | MERCK & CO. INC. | 22.6 | 302.459B | ||
| PFE | PFIZER INC | 8.87 | 152.718B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.97 | 122.756B | ||
| ZTS | ZOETIS INC | 18.75 | 56.091B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.7 | 26.039B | ||
| VTRS | VIATRIS INC | 6.29 | 18.405B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.89 | 12.521B | ||
| AXSM | AXSOME THERAPEUTICS INC | 224.33 | 9.385B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RETA
Company Profile
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. The company is headquartered in Plano, Texas and currently employs 321 full-time employees. The company went IPO on 2016-05-26. The firm concentrates on small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with few or no approved therapies. The firm's first product, SKYCLARYS (omaveloxolone), is used for the treatment of Friedreich's ataxia (FA) in adults and adolescents aged 16 years and older. The company is also engaged in developing cemdomespib, the lead product candidate from its Hsp90 modulator program, in neurological indications and Nrf2 activators for neurological diseases. Omaveloxolone activates the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation, in nonclinical models. Its Nrf2 activators are applicable to both rare diseases, such as Huntington's disease, progressive supranuclear palsy, frontotemporal dementia, primary progressive multiple sclerosis, and others.
Company Info
REATA PHARMACEUTICALS INC-A
5320 Legacy Dr
Plano TEXAS 75024 US
CEO: J. Warren Huff
Employees: 321
Phone: 19728652219.0
REATA PHARMACEUTICALS INC-A / RETA FAQ
What does RETA do?
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. The company is headquartered in Plano, Texas and currently employs 321 full-time employees. The company went IPO on 2016-05-26. The firm concentrates on small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with few or no approved therapies. The firm's first product, SKYCLARYS (omaveloxolone), is used for the treatment of Friedreich's ataxia (FA) in adults and adolescents aged 16 years and older. The company is also engaged in developing cemdomespib, the lead product candidate from its Hsp90 modulator program, in neurological indications and Nrf2 activators for neurological diseases. Omaveloxolone activates the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation, in nonclinical models. Its Nrf2 activators are applicable to both rare diseases, such as Huntington's disease, progressive supranuclear palsy, frontotemporal dementia, primary progressive multiple sclerosis, and others.
Can you provide the latest stock price for REATA PHARMACEUTICALS INC-A?
The current stock price of RETA is 172.36 USD. The price increased by 0.02% in the last trading session.
Does RETA stock pay dividends?
RETA does not pay a dividend.
What is the ChartMill rating of REATA PHARMACEUTICALS INC-A stock?
RETA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting RETA stock to perform?
15 analysts have analysed RETA and the average price target is 175.9 USD. This implies a price increase of 2.05% is expected in the next year compared to the current price of 172.36.
What is the GICS sector and industry of RETA stock?
REATA PHARMACEUTICALS INC-A (RETA) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the upcoming earnings date for REATA PHARMACEUTICALS INC-A?
REATA PHARMACEUTICALS INC-A (RETA) will report earnings on 2023-11-06, before the market open.